The Irish Times

Amarin – an overnight success 10 years in the making

After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market

Fri Oct 05 2018 - 05:50

Costs, including ongoing R&D, means the company reports loss of $21.9 million for the quarter and $115.2 million for full year

Thu Feb 25 2016 - 20:00

Company fails to persuade advisory panel to back exponential expansion of market for cardiovascular drug

Thu Oct 17 2013 - 20:22